Details

Autor(en) / Beteiligte

• Leng, Bin
• Chen, Xiao-jun
• Wang, Chang
• Zhou, An
• Chen, Qi-hua
• Liu, Yu
• Chen, Guo-chun
• Zhou, Lin
• Sun, Cui-fang
• Zhang, Hai-nan
• Yuan, Fang
• Liu, Hong

Titel

A short-term functional recovery comparison of therapeutic plasma exchange and immunoadsorption in severe acute neuroimmune diseases

Ist Teil von

• International immunopharmacology, 2024-10, Vol.140, p.112796, Article 112796

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Both therapeutic plasma exchange (TPE) and protein A immunoadsorption (PAIA) improve short-term neurological function in severe acute neuroimmune diseases.•At the three-month follow-up, the PAIA group showed a significantly higher rate of improvement in modified Rankin scale (mRS) scores compared to the TPE group.•The PAIA group demonstrated an earlier and significantly greater improvement in health-related quality of life (HRQoL) compared to the TPE group, as measured by the EQ-VAS score at 14 days post-treatment. To compare the differential impact of recombinant protein A immunoadsorption (PAIA) or therapeutic plasma exchange (TPE) on neurological functional improvement and quality of life in patients afflicted with severe acute neuroimmune diseases, including Guillain-Barré syndrome (GBS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), and anti-NMDA receptor encephalitis (NMDARE). The retrospective study included 29 patients with moderate to severe disability (modified Rankin scale, mRS≥3) due to acute neuroimmune diseases at the second Xiangya hospital from January 2021 to January 2023. The clinical efficacy of PAIA and TPE in improving neurological function (ΔmRS≥1) and the difference in favorable functional outcomes (mRS 0–2) at three months were evaluated. The impact of both treatments on patients’ health-related quality of life (HRQoL) was assessed using a visual analog scale (EQ-VAS) score ranging from 0 to 100. The findings revealed that the PAIA group exhibited a significantly higher rate of improvement in modified Rankin scale (mRS) scores (ΔmRS≥1) at the three-month follow-up compared to the TPE group (94.4 % vs. 54.5 %, p = 0.018). However, no statistically significant difference was observed between the two treatment modalities in terms of favorable neurological functional outcomes at the three-month mark. Furthermore, the PAIA group demonstrated a significantly higher EQ-VAS score at 14 days post-treatment compared to the TPE group (60.0 vs. 47.7, p = 0.017). In the short-term management of severe acute neuroimmune diseases, PAIA may present a greater probability of improving neurological function and facilitating an earlier enhancement of quality of life compared to TPE.